Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer

Abstract

Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.

1 - 15 . (canceled) 
     
     
         16 . A method of treating kidney cancer, comprising administering to a patient in need of such treatment N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, malate salt, wherein said salt is in crystalline Form N-2 and said Form N-2 is characterized by at least one of the following:
 (i) a solid state  13 C NMR spectrum with four or more peaks selected from 23.0, 25.9, 38.0, 41.7, 69.7, 102.0, 122.5, 177.3, 179.3, 180.0, and 180.3, ±0.2 ppm; 
 (ii) a powder x-ray diffraction pattern (CuKα λ=1.5418 Å) comprising 2θ values at 20.9±0.2°2θ and 21.9±0.2°2θ, and two or more 2θ values selected from: 6.4±0.2°2θ, 9.1±0.2°2θ, 12.0±0.2°2θ, 12.8±0.2, 13.7±0.2, 17.1±0.2, 22.6±0.2, 23.7±0.2, wherein measurement of the crystalline form is at room temperature; and/or 
 (iii) an x-ray powder diffraction (XRPD) pattern substantially in accordance with the pattern shown in  FIG. 8 . 
 
     
     
         17 . A method of treating kidney cancer, comprising administering to a patient in need of such treatment a pharmaceutical composition comprising N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, (L)-malate salt and a pharmaceutically acceptable carrier, wherein said salt is in crystalline Form N-2 and said Form N-2 is characterized by at least one of the following:
 (i) a solid state  13 C NMR spectrum with four or more peaks selected from 23.0, 25.9, 38.0, 41.7, 69.7, 102.0, 122.5, 177.3, 179.3, 180.0, and 180.3, ±0.2 ppm; 
 (ii) a powder x-ray diffraction pattern (CuKα λ=1.5418 Å) comprising 2θ values at 20.9±0.2°2θ and 21.9±0.2°2θ, and two or more 2θ values selected from: 6.4±0.2°2θ, 9.1±0.2°2θ, 12.0±0.2°2θ, 12.8±0.2, 13.7±0.2, 17.1±0.2, 22.6±0.2, 23.7±0.2, wherein measurement of the crystalline form is at room temperature; and/or 
 (iii) an x-ray powder diffraction (XRPD) pattern substantially in accordance with the pattern shown in  FIG. 8 .